The ability to design proteins to perform desired functions will transform drug development. In particular, with AI and machine learning, scientists gain the ability to engineer antibody-based drugs, including multispecifics which engage multiple targets. By altering existing protein structures or developing proteins de novo, biologics will become more effective and specific. In this episode, we talk to Suzanne Edavettal, the executive director of Protein Engineering at Amgen. We discuss how protein design affects drug development and success rates in the clinic today and in the future.

Speaker
Suzanne Edavettal, PhD
Executive Director
Protein Engineering
Amgen